This study looked at whether blood glucose control influenced heart disease and stroke for patients with type 2 diabetes (T2D). It found that patients with better blood glucose control had a lower risk of heart disease and stroke over the following 8 years.

This study is evaluating the effect of medically tailored meals and nutrition education via tele-health for patients with uncontrolled type 2 diabetes (T2D). The outcomes include changes in blood glucose control, body weight, and confidence in self-managing care. This study is taking place in Philadelphia, Pennsylvania, United States.

This study compared patients with type 2 diabetes (T2D) switching to either insulin glargine 300 (Toujeo) or insulin glargine 100 (Lantus). It found that both types of insulin glargine improved blood glucose control, and insulin glargine 300 had a lower risk of hypoglycemia (dangerously low blood glucose levels) outside of a clinical trial.

This study evaluated the safety and effectiveness of a combination treatment between sodium-glucose cotransporter 2 (SGLT) inhibitors and glucagon-like peptide 1 (GLP1) receptor agonists for patients with Type 2 diabetes (T2D). This study concluded that combination treatment improved blood glucose control and reduced weight loss for these patients.

This study examined the effectiveness and safety of two types of non-insulin drugs used in combination to treat patients with uncontrolled type 2 diabetes (T2D). The results showed that the drug combination effectively reduced patients’ blood glucose levels and body weight and did not cause serious side effects.

This study examined if patients with Type 1 diabetes (T1D) who followed a healthy or Mediterranean diet had a higher quality of life. The authors found that patients who followed the Mediterranean diet had a better quality of life, but neither diet improved patients’ satisfaction with treatment.

This study looked at the effects of drinking magnesium-rich balanced deep-sea water in patients with prediabetes. This study found that this deep-sea water improved insulin sensitivity in these patients.

This review looked at whether metformin (Glucophage) can reduce the risk of colorectal cancer for patients with diabetes. It found that patients who had been treated with metformin may have a lower risk of colorectal cancer.

This study evaluated empagliflozin (Jardiance) and linagliptin (Tradjenta) for the treatment of Type 2 diabetes (T2D). This study found that combining both drugs (Glyxambi) was more effective at lowering blood glucose levels than either medication alone, with similar side effects.

This study compared two insulin types – degludec (Tresiba) and glargine (Lantus) – to see which was better at reducing blood glucose levels before hypoglycemia (dangerously low blood glucose levels) occurred. The study found that degludec improved blood glucose levels for longer than glargine before patients experienced hypoglycemia.